Drug · DIN 02265982
BLEOMYCIN FOR INJECTION
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 25, 2016; first marketed March 20, 2009.
- Drug Identification Number (DIN)
- 02265982
- Company (DIN owner)
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Solution
- Route
- Subcutaneous; Intramuscular; Intravenous; Intrapleural
- Therapeutic class (ATC)
- Bleomycin L01DC01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BLEOMYCIN (BLEOMYCIN SULFATE) | 15 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 26, 2016: NOC 17819Abbreviated New Drug Submission (ANDS) · Manufacturer and product name change
- January 30, 2008: NOC 9341Abbreviated New Drug Submission (ANDS) · Manufacturer name change
- November 8, 2006: NOC 8395Abbreviated New Drug Submission (ANDS) · Manufacturer name change
- March 30, 2005: NOC 6377Abbreviated New Drug Submission (ANDS)
Other DINs named BLEOMYCIN FOR INJECTION
- DIN 02566346 · Approved